Edaravone, a novel free radical scavenger, demonstrates neuroprotective effects by inhibiting vascular endothelial cell injury and ameliorating neuronal damage in ischemic brain models. The present study was undertaken to verify its therapeutic efficacy following acute ischemic stroke. We performed a multicenter, randomized, placebo-controlled, double-blind study on acute ischemic stroke patients commencing within 72 h of onset. Edaravone was infused at a dose of 30 mg, twice a day, for 14 days. At discharge within 3 months or at 3 months after onset, the functional outcome was evaluated using the modified Rankin Scale. Two hundred and fifty-two patients were initially enrolled. Of these, 125 were allocated to the edaravone group and 125 to the placebo group for analysis. Two patients were excluded because of subarachnoid hemorrhage and disseminated intravascular coagulation. A significant improvement in functional outcome was observed in the edaravone group as evaluated by the modified Rankin Scale (p = 0.0382). Edaravone represents a neuroprotective agent which is potentially useful for treating acute ischemic stroke, since it can exert significant effects on functional outcome as compared with placebo.

Kontos HA: George E Brown memorial lecture. Oxygen radicals in cerebral vascular injury. Circ Res 1985;57:508–516.
Schmidley JW: Free radicals in central nervous system ischemia. Stroke 1990;21:1086–1090.
Halliwell B: Reactive oxygen species and the central nervous system. J Neurochem 1992;59:1609–1623.
Gaudet RJ, Levine L: Transient cerebral ischemia and brain prostaglandins. Biochem Biophys Res Commun 1979;86:893–901.
Moskowitz MA, Kiwak KJ, Hekimian K, Levine L: Synthesis of compounds with properties of leukotrienes C4 and D4 in gerbil brains after ischemia and reperfusion. Science 1984;224:886–889.
Asano T, Gotoh O, Koide T, Takakura K: Ischemic brain edema following occlusion of the middle cerebral artery in the rat. II. Alteration of the eicosanoid synthesis profile of brain microvessels. Stroke 1985;16:110–113.
Chan PH, Fishman RA, Longar S, Chen S, Yu A: Cellular and molecular effects of polyunsaturated fatty acids in brain ischemia and injury. Prog Brain Res 1985;63:227–235.
Watanabe T, Yuki S, Egawa M, Nishi H: Protective effects of MCI-186 on cerebral ischemia: Possible involvement of free radical scavenging and antioxidant actions. J Pharmacol Exp Ther 1994;268:1597–1604.
Watanabe T, Morita I, Nishi H, Murota S: Preventive effect of MCI-186 on 15-HPETE induced vascular endothelial cell injury in vitro. Prostaglandins Leukot Essent Fatty Acids 1988;33:81–87.
Abe K, Yuki S, Kogure K: Strong attenuation of ischemic and postischemic brain edema in rats by a novel free radical scavenger. Stroke 1988;19:480–485.
Nishi H, Watanabe T, Sakurai H, Yuki S, Ishibashi A: Effect of MCI-186 on brain edema in rats. Stroke 1989;20:1236–1240.
Kawai H, Nakai H, Suga M, Yuki S, Watanabe T, Saito K: Effects of a novel free radical scavenger, MCI-186, on ischemic brain damage in the rat distal middle cerebral artery occlusion model. J Pharmacol Exp Ther 1997;281:921–927.
Mizuno A, Umemura K, Nakashima M: Inhibitory effect of MCI-186, a free radical scavenger, on cerebral ischaemia following rat middle cerebral artery occlusion. Gen Pharmacol 1998;30:575–578.
Yamamoto T, Yuki S, Watanabe T, Mitsuka M, Saito K, Kogure K: Delayed neuronal death prevented by inhibition of increased hydroxyl radical formation in a transient cerebral ischemia. Brain Res 1997;762:240–242.
Nakagomi T, Yamakawa K, Sasaki T, Saito I, Takakura K: Effect of edaravone on cerebral vasospasm following experimental subarachnoid hemorrhage. J Stroke Cerebrovasc Dis, in press.
Otomo E, Tohgi H, Kogure K, Hirai S, Terashi A, Gotoh F, Tazaki Y, Ito E, Sawada T, Kobayashi S, Fujishima M, Nakashima M: Clinical efficacy of a free radical scavenger, MCI-186, on acute cerebral infarction: Early phase II clinical trial. Ther Res 1998;19:1311–1332.
MCI-186 Acute Cerebral Infarction Study Group: Late phase 2 clinical trial of MCI-186 on acute cerebral infarction: A dose-finding double-blind study (in Japanese). J Clin Exp Med 1998;185:841–863.
Ohta T, Kikuchi H, Hashi K, Kudo Y: Nizofenone administration in the acute stage following subarachnoid hemorrhage: Results of a multi-center controlled double-blind clinical study. J Neurosurg 1986;64:420–426.
Minematsu K, Yamaguchi T, Omae T: Spectacular shrinking deficit: Rapid recovery from a major hemispheric syndrome by migration of an embolus. Neurology 1992;42:157–162.
van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJA, van Gijn J: Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988;19:604–607.
Barinaga M: Finding new drugs to treat stroke. Science 1996;272:664–666.
Astrup J, Siesjo BK, Symon L: Thresholds in cerebral ischemia: The ischemic penumbra. Stroke 1981;12:723–725.
Hossmann KA: Viability thresholds and the penumbra of focal ischemia. Ann Neurol 1994;36:557–565.
Fisher M: Characterizing the target of acute stroke therapy. Stroke 1997;28:866–872.
Houkin K, Nakayama N, Kamada K, Noujou T, Abe H, Kashiwaba T: Neuroprotective effect of the free radical scavenger MCI-186 in patients with cerebral infarction: Clinical evaluation using magnetic resonance imaging and spectroscopy. J Stroke Cerebrovasc Dis 1998;7:1–9.
Yamamoto Y, Kuwahara T, Watanabe K, Watanabe K: Antioxidant activity of 3-methyl-1-phenyl-2-pyrazolin-5-one. Redox Rep 1996;2:333–338.
Takamatsu Y, Watanabe T: Studies on the concentrations of 3-methyl-1-phenyl-2-pyrazolin-5-one (MCI-186) in dog plasma and cerebral spinal fluid. Jpn Pharmacol Ther 1997;25(suppl):1793–1797.
Ando K, Nishi H, Watanabe T, Watanabe Y, Yuki S, Sugasawa K, Horii D, Ishibashi A, Kimura A, Nakano D, Morinaga T: General pharmacological studies of 3-methyl-1-phenyl-2-pyrazolin-5-one (MCI-186), a novel radical scavenging agent. Jpn Pharmacol Ther 1997;25(suppl):1723–1753.
Watanabe Y, Watanabe T, Ando K, Yuki S, Saito K, Ishibashi A: Drug interaction between radical scavenger, 3-methyl-1-phenyl-2-pyrazolin-5-one (MCI-186), and stroke-medicating agents. Jpn Pharmacol Ther 1997;25(suppl):1709–1718.
Takamatsu Y, Yuki S, Watanabe T: Studies on the concentrations of 3-methyl-1-phenyl-2- pyrazolin-5-one (MCI-186) in MCA occlusion and reperfusion model of rats. Jpn Pharmacol Ther 1997;25(suppl):1785–1791.
Shibata H, Arai S, Izawa M, Murasaki M, Takamatsu Y, Izawa O, Takahashi C, Tanaka M: Phase I clinical study of MCI-186 (edaravone, 3-methyl-1-phenyl-2-pyrazoline-5-one) in healthy volunteers: Safety and pharmacokinetics of single and multiple administrations. Jpn J Clin Pharmacol Ther 1998;29:863–876.
Yokota S, Kumagai Y, Uchiumi M, Isawa S, Murasaki M, Akimoto K, Iwamoto M, Yuasa T, Iwano M: A pharmacokinetic study of MCI-186, a novel drug for cerebrovascular disease in elderly and young healthy subjects. Jpn J Clin Pharmacol Ther 1997;28:693–702.
Gotoh O, Koide T, Asano T, Takakura K, Tamura A, Sano K: A model to study ischemic brain edema in rats and the influence of drugs; in Go KG, Baethmann A (eds): Recent Progress in the Study and Therapy of Brain Edema. Plenum Press, 1984, pp 499–508.
Matsui T, Mori T, Tateishi N, Kagamiishi Y, Satoh S, Katsube N, Morikawa E, Morimoto T, Ikuta F, Asano T: Astrocytic activation and delayed infarct expansion after permanent focal ischemia in rats. I. Enhanced astrocytic synthesis of s-100β in the periinfarct area precedes delayed infarct expansion. J Cereb Blood Flow Metab 2002;22:711–722.
Peters O, Back T, Lindauer U, Busch C, Megow D, Dreier J, Dirnagl U: Increased formation of reactive oxygen species after permanent and reversible middle cerebral artery occlusion in the rat. J Cereb Blood Flow Metab 1998;18:196–205.
Wang PY, Kao CH, Mui MY, Wang SJ: Leukocyte infiltration in acute hemispheric ischemic stroke. Stroke 1993;24:236–240.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.